%PDF-1.4
%
74 0 obj
<>
endobj
71 0 obj
<>
endobj
144 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-09-13T13:42:34Z
2024-03-28T14:22:07-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T14:22:07-07:00
application/pdf
Heather
2003-563.oct
uuid:c9a933f8-1dd1-11b2-0a00-5608275dc400
uuid:c9a933fa-1dd1-11b2-0a00-810000000000
endstream
endobj
60 0 obj
<>
endobj
61 0 obj
<>
endobj
75 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 44 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 46 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 48 0 R/Type/Page>>
endobj
17 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 50 0 R/Type/Page>>
endobj
35 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 52 0 R/Type/Page>>
endobj
38 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 54 0 R/Type/Page>>
endobj
166 0 obj
[170 0 R]
endobj
167 0 obj
<>stream
q
0 0 612 783 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6283 0.7779 -0.7779 0.6283 8.2321 49.765 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 783 m
0 783 l
f
q
-1 784 587 -785 re
W n
q
0 783.03 612 -783 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 63.4 732.5293 Tm
(synovial samples and synovial membrane-like interface tissue from)Tj
0 -1.25 TD
(aseptic loosening of total hip replacement. Rheumatol Int)Tj
0 Tc 0 Tw T*
(2000;19:177-83.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875.1 (Schmidt-Rohlfing B, Gavenis K, Kippels M, Schneider U. New)]TJ
2.175 -1.25 Td
(potential markers for cartilage degradation of the knee joint. Scand)Tj
T*
(J Rheumatol 2002;31:151-7.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (Spring J, Beck K, Chiquet-Ehrismann R. )17.7 (T)69.9 (wo contrary functions of)]TJ
2.175 -1.25 Td
(tenascin: dissection of the active sites by recombinant tenascin)Tj
T*
(fragments. Cell 1989;59:325-34.)Tj
-2.175 -1.25 Td
[(24.)-875.1 (Aukhil I, Joshi P)110.7 (,)-0.1 ( )36.8 (Y)99.8 (an )36.8 (Y)128.9 (, Erickson HP)110.7 (. Cell- and heparin-binding)]TJ
2.175 -1.25 Td
(domains of the hexabrachion arm identified by tenascin expression)Tj
T*
(proteins. J Biol Chem 1993;268:2542-53.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Jones PL, Jones FS. )17.7 (T)69.9 (enascin-C in development and disease: gene)]TJ
2.175 -1.25 Td
(regulation and cell function. Matrix Biology 2000;19:581-96.)Tj
-2.175 -1.25 Td
[(26.)-875.1 (T)69.9 (sunoda )17.7 (T)74 (, Inada H, Kalembeyi I, et al. Involvement of lar)17.7 (ge)]TJ
2.175 -1.25 Td
[(tenascin-C splice variants in breast cancer progression. )54.8 (Am J Pathol)]TJ
0 Tc 0 Tw T*
(2003;162:1857-67.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(27.)-875.1 (Altman R, )54.8 (Asch E, Bloch D, et al. Development of criteria for the)]TJ
2.175 -1.25 Td
(classification and reporting of osteoarthritis. Classification of)Tj
T*
[(osteoarthritis of the knee. )54.8 (Arthritis Rheum 1986;29:1039-49.)]TJ
-2.175 -1.25 Td
[(28.)-875.1 (Imanaka-Y)99.8 (oshida K, Hiroe M, )36.8 (Y)99.8 (asutomi )36.8 (Y)128.9 (, et al. )17.7 (T)69.9 (enascin-C is a)]TJ
2.175 -1.25 Td
(useful marker for disease activity in myocarditis. J Pathol)Tj
0 Tc 0 Tw T*
(2002;197:388-94.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(29.)-875.1 (Borsi L, Carnemolla B, Nicol\230 G, Spina B, )17.7 (T)69.9 (anara G, Zardi L.)]TJ
2.175 -1.25 Td
[(Expression of dif)17.7 (ferent tenascin isoforms in normal, hyperplastic)]TJ
T*
(and neoplastic human breast tissues. Int J Cancer 1992;52:688-92.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (Hindermann )17.7 (W)91.9 (, Berndt )54.8 (A, Borsi L, et al. Synthesis and protein)]TJ
2.175 -1.25 Td
[(distribution of the unspliced lar)17.7 (ge tenascin-C isoform in oral )]TJ
T*
(squamous cell carcinoma. J Pathol 1999;189:475-80.)Tj
30.825 35 Td
[(31.)-875.1 (Ghert MA, Jung ST)73.9 (, Qi )17.7 (W)91.8 (, et al. )17.7 (The clinical significance of)]TJ
2.175 -1.25 Td
(tenascin-C splice variant expression in chondrosarcoma. Oncology)Tj
0 Tc 0 Tw T*
(2001;61:306-14.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(32.)-875.1 (Ghert MA, Qi )17.7 (W)91.8 (, Erickson HP)110.7 (, Block JA, Scully SP)110.7 (. )17.7 (T)69.9 (enascin-C)]TJ
2.175 -1.25 Td
(expression and distribution in cultured human chondrocytes and)Tj
T*
(chondrosarcoma cells. J Orthop Res 2002;20:834-41.)Tj
-2.175 -1.25 Td
[(33.)-875.1 (Chiquet-Ehrismann R, Matsuoka )36.8 (Y)128.9 (, Hofer U, Spring J, Bernasconi)]TJ
2.175 -1.25 Td
[(C, Chique M. )17.7 (T)69.9 (enascin variants: dif)17.7 (ferential binding to fibronectin)]TJ
T*
(matrix assembly and distinct distribution in cell cultures and)Tj
T*
(tissues. Cell Regul 1991;2:927-38.)Tj
-2.175 -1.25 Td
[(34.)-875.1 (Siri )54.8 (A, Knauper )17.7 (V)128.9 (,)-0.1 ( )17.7 (V)110.8 (eirana N, Caocci F)79.7 (, Murphy G, Zardi L.)]TJ
2.175 -1.25 Td
[(Dif)17.7 (ferent susceptibility of small and lar)17.7 (ge human tenascin-C)]TJ
T*
(isoforms to degradation by matrix metalloproteinases. J Biol Chem)Tj
0 Tc 0 Tw T*
(1995:270:8650-4.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(35.)-875.1 (Knauper )17.7 (V)128.9 (, Cowell S, Smith B, et al. )17.7 (The role of the C-terminal)]TJ
2.175 -1.25 Td
(domain of human collagenase-3 \(MMP-13\) in the activation of)Tj
T*
[(procollagenase-3, substrate specificity)64.8 (, and tissue inhibitor of)]TJ
T*
(metalloproteinase interaction. J Biol Chem 1997;272:7608-16.)Tj
-2.175 -1.25 Td
[(36.)-875.1 (Y)99.8 (oshida H, Fujita S, Nishida M, Iizuka )17.7 (T)74 (,)-0.1 ( )36.8 (Y)99.8 (oshida )17.7 (T)74 (, Sakakura )17.7 (T)74 (.)]TJ
2.175 -1.25 Td
[(The expression of tenascin mRNA)-220.2 (in human temporomandibular)]TJ
T*
(joint specimens. J Oral Rehabil 2002;29:765-9.)Tj
-2.175 -1.25 Td
[(37.)-875.1 (Mackie EJ, )17.7 (T)35 (ucker RP)110.7 (. )17.7 (T)69.9 (enascin in bone morphogenesis: expression)]TJ
2.175 -1.25 Td
(by osteoblasts and cell type-specific expression of splice variants. )Tj
T*
(J Cell Sci 1992;103:765-71.)Tj
-2.175 -1.25 Td
[(38.)-875.1 (T)69.9 (anaka M, )36.8 (Y)99.8 (amazaki )17.7 (T)74 (,)-0.1 ( )54.8 (Araki N, et al. Clinical significance of)]TJ
2.175 -1.25 Td
(tenascin-C expression in osteosarcoma: tenascin-C promotes distant)Tj
T*
(metastases of osteosarcoma. Int J Mol Med 2000;5:505-10.)Tj
ET
0 0 0 1 K
43 72 m
547 72 l
S
BT
/T1_2 1 Tf
8 0 0 8 409.3613 53.9844 Tm
(The Journal of Rheumatology 2004; 31:10)Tj
0 Tc 0 Tw -45.7952 -0.0313 Td
(2026)Tj
ET
0 0 0 0 k
/GS0 gs
97.25 76.75 396.47 -10.83 re
f*
0.5 w
97.25 76.75 396.47 -10.83 re
S
Q
Q
q
0 0 612 783 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
110.368 69 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 8 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
54 0 obj
<>stream
8;Z\6!KP#N%.jK`R.$Qt&j,JlA\]X4VcYW\K[b1n'XPdq!07B/YJBkaDJZedJ)&p)
"lE#^q\;1[`'paP,abHq.?cPP?Kt+4(A5bQb3e/fiKnngB5*_gdHVrF=#@Ugi]UF
8USd1<1jrS&!0u;CEEFY-c>#cpcXIsGWdE`B;cuNSSbBe2MMTAlMV\T;Tk,)?^VSF
X8jT41/!7bj0`:6;5_+"8qdtD#1R)tXu+)2MQSX6i&3iLa4t2eME(ollme8sqp5^(+&ul5Umj)M-`$oXba64fY*K(fr"BZ^H*p:Lh\fr@D0W*`G>'IDp@ia
h9Y:)
endstream
endobj
58 0 obj
[/Indexed/DeviceRGB 255 57 0 R]
endobj
57 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
131 0 obj
<>
endobj
81 0 obj
<>
endobj
78 0 obj
<>
endobj
118 0 obj
<>
endobj
149 0 obj
<>
endobj
77 0 obj
<>
endobj
111 0 obj
<>stream
HU{PSgM.U H"EkGEDhu**]^`)D$< g yhQUQ+Uݭeڞ~#j;g7ߜ|3;YZ`8;l[)LHVnƧoa3,WYh<&b51nmM(/lҵWY;fpӶEh8Nնw\U.e?^7-&D*HEx уMI@eξ}1_(DAj_t$LIeo ?>-qH$ a0^,H~}?c9y-qql
|0lmq6mB#\ڒL#Q/ەESz+;Vss"\6j.Xˬ9/`^qL3濰)alvvSk;~-ܷb^'Iy1,?" ;kN(j|U1WZ#N͓)XU D~Ch,p0C<En;(ef\9&!|>EA-@K㺳FW?8,ǠlO|<>U\NBM;mFL:2S8M\<8eG6`Mhm
rvJ=פhy?&wɓpei`'Ė*+kxG8`eJh?awjtI% JpdQ[,Ut7mtU~,p?r'2㎹9i#8\xB@#vDqktY_;%0QQ8GSw]*+G&˄F*쳃bE`u xdKՋ{/ۦ/f|㞺U~ڬRuZWf>}`x6ѳudX rj'ȟ|:KV "Ql2Yp^sm`Q
=$"3
'HVE&Ibu
+*8&&oHѯCZTz{Gfq: m;9
*j}U2=6nT,~ؤܳ z4+'U JSͥ$}}7rW5dw
dyxCaNJQoȹL ,g#ZԨ&{Z炖5KH~bL>Sfrik=6aɁNN͌mddwGNɞ܈FQ7]+WIsI'(mM6u{vm;)pt30m#ϿUH`_*6٘/k+7/Pxx3t/?{
a;<&V%F'qcZQ╃,'͉_:upPsѦO*JJrSN`S6
|(B⚿zuGAmQg.nPO{MV'T^)U}GpTA
ٰYiRȢC~ t3/n荕AiilTQIՇJrJj҆&)^Kb
8cA0v&oz k'57 VܭKmV2@FFEޱ~5=f
f5-e1uxd,2LÆ`:vQ]uB(:ݸu4ԴT5j[4
*a1y%ڼaumƏr (t
!.RSOݗuʦ\(EX^;,.8RXe}=8`/lB ,+GnO|hh1aXgeaPu-\t{:߄VyTSwnKl-orszV^QEqKl aK }5Hetu3}_g^:{~e:]Wwf8tvȠ`)vR&&(ۃdbi>i⾽^KǪuy^Oo%<
ʨx#;mL
ܶD|{Jd(QCv'
f
K($7'!TLB3µ~Y!)м^#ɒ4\o|˼a?ƋF12K'#bᔌXvaNP8F?xⵞ!Na*ߌALG&u;VJ!AhhD